Daily Stock Analysis, CORT, Corcept Therapeutics Inc, priceseries

Corcept Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
9.98
Close
10.12
High
10.25
Low
9.88
Previous Close
9.99
Daily Price Gain
0.13
YTD High
11.40
YTD High Date
Mar 13, 2017
YTD Low
6.70
YTD Low Date
Jan 31, 2017
YTD Price Change
2.76
YTD Gain
37.50%
52 Week High
11.40
52 Week High Date
Mar 13, 2017
52 Week Low
4.12
52 Week Low Date
Mar 29, 2016
52 Week Price Change
5.91
52 Week Gain
140.38%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 12. 2015
3.14
Feb 27. 2015
3.32
10 Trading Days
5.75%
Link
LONG
Mar 11. 2015
3.86
Apr 16. 2015
6.04
25 Trading Days
56.38%
Link
LONG
Nov 17. 2015
4.85
Dec 7. 2015
5.21
13 Trading Days
7.36%
Link
LONG
May 13. 2016
4.93
Jun 7. 2016
5.58
16 Trading Days
13.10%
Link
LONG
Sep 14. 2016
5.75
Oct 11. 2016
6.41
19 Trading Days
11.41%
Link
LONG
Nov 2. 2016
7.51
Nov 22. 2016
8.99
14 Trading Days
19.66%
Link
LONG
Feb 22. 2017
8.51
Mar 14. 2017
9.69
14 Trading Days
13.83%
Link
Company Information
Stock Symbol
CORT
Exchange
NasdaqCM
Company URL
http://www.corcept.com
Company Phone
650.688.8803
CEO
Joseph K. Belanoff
Headquarters
California
Business Address
149 COMMONWEALTH DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001088856
About

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Description

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. Its products include Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, Korlym's active ingredient, which is in Phase I/II clinical trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with metastatic, triple-negative breast cancer, a form of solid-tumor cancer with a particularly poor prognosis; and CORT125134 that is in Phase I clinical trials for the treatment of patients with Cushing's syndrome and solid-tumor cancers. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.